# Alvotech Files European Application for Eylea Biosimilar AVT29

- URL: https://stocks.freetheai.org/news/alvotech-files-european-application-for-eylea-biosimilar-avt29-40186d
- Published: 2026-10-14T08:30:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:ALVO](https://stocks.freetheai.org/symbols/NASDAQ-ALVO)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Alvotech (ALVO) has submitted a regulatory application to the European Medicines Agency for AVT29, a proposed biosimilar to 8 milligram Eylea. The filing was submitted as a line extension to Mynzepli, the company's previously approved 2 milligram aflibercept treatment. The submission marks the first known regulatory filing worldwide for an 8 milligram Eylea biosimilar.

The expansion into the higher-dose 8 milligram formulation targets a significant portion of the eye treatment market, as the 8 milligram strength accounted for approximately 57% of Eylea sales during the second quarter of 2026. By submitting the candidate as a line extension, the review process could be streamlined using existing approvals. Advanz is set to handle commercialization of the biosimilar across Europe once authorized.

Investors and market participants will be monitoring the regulatory review process with European authorities. Key factors moving forward include the potential regulatory approval, official launch timelines, commercial pricing strategies, and any intellectual property or patent hurdles that could impact market entry.

## Key points

- Alvotech filed a regulatory submission with the European Medicines Agency for AVT29, a proposed biosimilar to 8 mg Eylea.
- This submission is the first known regulatory filing globally for an 8 mg Eylea biosimilar candidate.
- The filing was submitted as a line extension to Mynzepli, Alvotech's approved 2 mg aflibercept product.
- The 8 mg dose accounted for roughly 57% of total Eylea sales in the second quarter of 2026.
- Advanz will handle commercial distribution of the treatment in Europe following regulatory approval.

## Questions and answers

### What did Alvotech file with European regulators?

Alvotech submitted a regulatory application to the European Medicines Agency for AVT29, a proposed biosimilar to 8 mg Eylea, as a line extension to its approved 2 mg product Mynzepli.

### Why is the Eylea 8 mg biosimilar filing significant?

It is the first known global regulatory filing for an 8 mg Eylea biosimilar, targeting a high-dose market segment that generated about 57% of Eylea sales in Q2 2026.

### Who will sell Alvotech's AVT29 in Europe?

Advanz has been selected to commercialize AVT29 across Europe following potential regulatory approval.